Cure My Disease

Don't miss your cure!

 Log in / Sign up

The carbon label on your inhaler: can it sway a Doctor's choice?

NCT ID NCT07825441

Knowledge-focused Sponsor: Portsmouth Hospitals NHS Trust Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 17, 2026 · Last updated Sep 18, 2026 · Updated 1 time

Summary

Metered-dose inhalers release propellant gases that add to the NHS carbon footprint, while dry powder inhalers do not. Researchers want to know whether giving NHS clinicians the carbon footprint of each inhaler changes which device they prefer for asthma patients. The trial asks more than 3,700 doctors, nurses, and pharmacists to review case scenarios and choose inhalers, with some receiving carbon footprint data and others receiving standard guidelines only. The goal is to understand whether environmental impact becomes part of prescribing decisions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Inhaler guidelines with carbon footprint information
What this could lead to
If carbon footprint labels sway prescribing, greener inhalers could become a routine part of asthma care and cut NHS emissions.
What could go wrong
This trial measures what clinicians say they prefer in written scenarios, not what they prescribe in real clinics. Stated choices may not match real-world behavior.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

3,782 people

The number who actually took part.

Started

Mar 2022

Finished

Aug 2025

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged ≥18 years * Working as an HCP within the NHS in a primary or secondary care setting * Able to provide written e-consent * Able to understand and complete the clinical case scenarios Exclusion Criteria: * Inability to understand or comply with study procedures and/or inability to give fully informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Asthma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Asthma

Contacts and locations

Locations

  • Portsmouth Hospitals University NHS Trust, Research Department

    Portsmouth, Hampshire, PO63LY, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.